Temporal Effects of Combined Birinapant and Paclitaxel on Pancreatic Cancer Cells Investigated via Large-Scale, Ion-Current-Based Quantitative Proteomics (IonStar)

Despite decades of effort, pancreatic adenocarcinoma (PDAC) remains an intractable clinical challenge. An insufficient understanding of mechanisms underlying tumor cell responses to chemotherapy contributes significantly to the lack of effective treatment regimens. Here, paclitaxel, a first-line che...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Mol Cell Proteomics
Autors principals: Wang, Xue, Niu, Jin, Li, Jun, Shen, Xiaomeng, Shen, Shichen, Straubinger, Robert M., Qu, Jun
Format: Artigo
Idioma:Inglês
Publicat: The American Society for Biochemistry and Molecular Biology 2018
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5880105/
https://ncbi.nlm.nih.gov/pubmed/29358341
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1074/mcp.RA117.000519
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars